The shadow of two reported patients’ deaths hovers over Eisai Co Ltd. and Biogen Inc.’s Alzheimer’s disease treatment, lecanemab, as the companies prepare to present phase III study data on the drug later today at the 15th Clinical Trials on Alzheimer's Disease conference. Read More
Nearing the end of 2022, the COVID-19 pandemic clearly no longer dominates the clinical activity reported by biopharma companies. Overall clinical data tracked by BioWorld is down significantly, as is the proportion focused on the SARS-Cov-2 virus. Therapeutics and vaccines targeting cancer, infectious diseases and neurological disorders, however, remain a stronghold. Read More
A computational platform that used single-cell RNA sequencing (scRNA-seq) data could quickly predict the best chemical compounds to use to convert cells from one type into another for use in research or cell therapies. The work, published in the Nov. 17, 2022, issue of Stem Cell Reports, was a collaboration between the lab of Hongkui Deng, a professor and director of the Key Laboratory of Cell Proliferation and Differentiation at Peking University in Beijing, and the lab of Antonio del Sol, a professor at the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg. Read More
A combination of radiation therapy and CD47 blockade induced an abscopal effect in animal studies even in animals that lacked T cells, researchers reported in the Nov. 21, 2022, online issue of Nature Cancer. Read More
With only a year to go before 100% compliance with the U.S. Drug Supply Chain Security Act’s serialization provisions will be required from the beginning to the end of the drug supply chain, most biopharma manufacturers are pretty confident they’re ready for the Nov. 27, 2023, deadline. But distributors? Not so much. And they lay the blame at the manufacturers’ feet. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Bristol Myers Squibb, Grünenthal, Kyowa Kirin, Lyvgen, Sumitomo. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Clarity, Immorna, Innocare, Junshi, Revive, Takeda, Triastek. Read More
